Biomedical Engineering Reference
In-Depth Information
76. Lievre A, Bachet JB, Le Corre D,
KRAS mutation status is predictive
of response to cetuximab therapy in colorectal cancer.
et al.
Cancer Res
2006;
66: 3992-3995. doi:10.1158/0008-5472.CAN-06-0191.
77. Lievre A, Bachet JB, Boige V,
KRAS mutations as an independent
prognostic factor in patients with advanced colorectal cancer treated
with cetuximab.
et al.
J Clin Oncol
2008; 26: 374-379. doi:10.1200/
JCO.2007.12.5906.
78. Khambata-Ford S, Garrett CR, Meropol NJ,
Expression of epiregulin
and amphiregulin and K-ras mutation status predict disease control
in metastatic colorectal cancer patients treated with cetuximab.
et al.
J Clin
2007; 25: 3230-3237. doi:10.1200/JCO.2006.10.5437.
79. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F,
Oncol
Oncogenic
activation of the RAS/RAF signaling pathway impairs the response
of metastatic colorectal cancers to anti-epidermal growth factor
receptor antibody therapies.
et al.
Cancer Res
2007; 67: 2643-2648.
doi:10.1158/0008-5472.CAN-06-4158.
80. Amado RG, Wolf M, Peeters M,
Wild-type KRAS is required for
panitumumab efficacy in patients with metastatic colorectal cancer.
et al.
J
2008; 26: 1626-1634. Published on 20080303. doi:10.1200/
JCO.2007.14.7116.
81. Bokemeyer C, Bondarenko I, Makhson A,
Clin Oncol
Fluorouracil, leucovorin,
and oxaliplatin with and without cetuximab in the first-line treatment
of metastatic colorectal cancer.
et al.
2009; 27: 663-671.
Published on 20081229. doi:10.1200/JCO.2008.20.8397.
82. De Roock W, Jonker DJ, Di Nicolantonio F,
J Clin Oncol
Association of KRAS
p.G13D mutation with outcome in patients with chemotherapy-
refractory metastatic colorectal cancer treated with cetuximab.
et al.
JAMA
2010; 304: 1812-1820. doi:10.1001/jama.2010.1535.
83. Raman M, Chen W, Cobb MH. Differential regulation and properties
of
MAPKs.
Oncogene
2007; 26: 3100-3112. doi:10.1038/
sj.onc.1210392.
84. Davies H, Bignell GR, Cox C,
et al.
Mutations of the BRAF gene in
2002; 417: 949-954. Published on 20020609.
doi:10.1038/nature00766.
85. Pollock PM, Harper UL, Hansen KS,
human cancer.
Nature
et al.
High frequency of BRAF
mutations in nevi.
Nat Genet
2003; 33: 19-20. Published on 20021125.
doi:10.1038/ng1054.
86. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal
cancer.
N Engl J Med
2009; 361: 98-99. doi:10.1056/NEJMc0904160.
